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Abstract
Background: Thyroid dysfunction is the most common autoimmune endocrine disorder in women of reproductive
age, and is associated with menstrual irregularities, anovulation and infertility. Whether it is thyroid function or
thyroid autoimmunity that affects functional ovarian reserve (FOR, i.e., the small growing ovarian follicle pool)
reflected in anti-Müllerian hormone (AMH) has, however, remained under dispute.
Methods: We investigated in 225 infertile women whether thyroid function, after adjustment for thyroid autoimmunity,
affects FOR within what is considered normal thyroid function (TSH, 0.4–4.5μIU/mL) by assessing AMH levels
in reference to TSH levels, stratified for TSH < or ≥3.0μIU/mL. Thyroid autoimmunity was defined by presence
of anti-thyroid peroxidase, −thyroglobulin and/or -thyroid receptor antibodies.
Results: Mean age of studied women was 38.4 ± 5.0 years; their mean AMH was 1.3 ± 2.0 ng/mL and mean
TSH 1.8 ± 0.9 μIU/mL. Thyroid autoimmunity was present in 11.1 % of patients. Women with TSH <3.0μIU/mL
presented with significantly higher AMH compared to those with TSH ≥3.0μIU/Ml (P = 0.03). This difference
remained significant after adjustment for thyroid autoimmunity as well as age (P = 0.02).
Conclusions: Even after adjustment for thyroid autoimmunity and age, TSH <3.0μIU/mL in euthyroid infertility
patients is associated with significantly better FOR (higher AMH) than TSH ≥3.0μIU/mL. This observation suggests a direct
beneficial effect of lower TSH levels on follicular recruitment, and warrants investigations of thyroxin supplementation in
infertile women with TSH levels ≥3.0μIU/mL in attempts to improve FOR.
Keywords: Thyroid stimulating hormone (TSH), Infertility, Ovarian reserve, Thyroid function, Thyroid autoimmunity,
Anti-Müllerian hormone (AMH)
Background
Thyroid dysfunction is the most common endocrine
disorder in women of reproductive age. Overt and
subclinical hypothyroidism may cause menstrual ir-
regularities and anovulation [1], and has been associ-
ated with female infertility [2]. These observations
have led to the commonly adopted clinical practice of
supplementing women trying to conceive with thy-
roxin if their TSH levels are ≥2.5 μIU/mL [3]. Investi-
gations of this TSH cut off resulted, however, in
conflicting results [4–6]: Reh et al., reported compar-
able pregnancy and delivery rates in euthyroid in vitro
fertilitzation (IVF) patients with TSH cut offs of 2.5
μIU/mL and 4.5 μIU/mL [7], while Murto et al. iden-
tified TSH <2.5 μIU/mL and anti-Müllerian hormone
(AMH) ≥10pmol/L (1.4 ng/ml) as significant predic-
tors of live births in women with unexplained infertil-
ity [8].
Based on such diverging findings, some suggested that
a TSH 2.5 μIU/mL may be too low to impair reproduct-
ive function [9]; others suggested that, as estrogen con-
centrations rise during follicular development, more
thyroxin is bound, leaving less free thyroid hormone
available for clinical utilization. As a result, TSH levels
increase [10, 11].
During controlled ovarian hyperstimulation (COH),
TSH increases 50–80 % from cycle start to ovulation in-
duction with human chorionic gonadotropin (hCG),
though most patients will around ovulation still experi-
ence TSH concentrations < 2.5 μIU/mL [9, 12]. Those
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with initial TSH above 3.0 μIU/mL at cycle start will, how-
ever, likely experience significant clinical hypothyroidism.
How abnormal thyroid function affects female fertility
remains unknown. Reported associations with menstrual
irregularities and anovulation in hypothyroidism suggest
that thyroid dysfunction might impair follicular growth
and maturation [13]. Assuming this to be the case, TSH
levels should influence AMH concentrations, independ-
ent of thyroid autoimmunity and female age. A recent
report by Busnelli et al. supports such an assumption by
demonstrating increasing TSH levels during COH, and a
trend toward lower AMH concentrations in women with
TSH levels ≥ 2.5μIU/mL seeking fertility treatments [12].
AMH is produced by small growing follicles, from pri-
mary up to small antral follicles and, therefore, reflects
what is called functional ovarian reserve (FOR) [14]. If
thyroid function affects follicular growth and develop-
ment, higher AMH concentrations should be observed
in women with lower TSH levels independent of thyroid
autoimmunity and female age. This study was designed
to investigate this hypothesis.
Methods
Study population
This study investigated 225 infertile women who be-
tween July 2009 and March 2014 underwent an initial
work up prior to fertility treatments at the Center for
Human Reproduction (CHR) in New York. Only women
with normal TSH levels (i.e., TSH 0.4–4.5μIU/mL) were
eligible for enrollment. As AMH levels decrease under
oral contraceptives (OC) and during pregnancy [15, 16],
pregnancy and OC usage up to three months prior to
testing served as exclusion criteria.
Laboratory assays
As part of routine pre-IVF evaluations, AMH, TSH and
thyroid antibody status, i.e. anti-thyroid peroxidase
(TPO), −thyroglobulin (TG) and –thyroid receptor anti-
bodies are assessed. TSH assessments were made in
blood serum, using standard commercial third gener-
ation electrochemiluminescence immunoassay, with ref-
erence values of 0.4–4.5 μIU/mL as normal range. This
normal TSH range was subdivided into low- and high-
normal ranges, based on TSH levels < or ≥ 3.0 μIU/mL.
AMH levels were assessed in blood serum by a 2nd
generation Beckman Coulter assay, with values being log-
transformed to account for skew among study subjects.
Thyroid autoantibodies were assessed in blood serum,
utilizing electrochemiluminescence immunoassay.
Ovarian stimulation
COH for IVF was strictly standardized, with only two
ovarian stimulation protocols in use: Women with nor-
mal FOR (NFOR) under age 38 were stimulated in long
agonist cycles with 150–300 IU of gonadotropins daily;
while women above age 38 and with low FOR (LFOR)
for age (defined as outside of the 95 % CI for age of FSH
and/or AMH) were stimulated in a microdose agonist
cycle with 450–600 IU of gonadotropins daily. Both
study groups involved similar distributions of both
stimulation protocols.
Statistics
Low-normal and high-normal TSH was compared using
a two-sampled t-test for continuous variables and a two-
sided Fisher exact test for categorical variables. Since
there was a statistical difference in AMH and thyroid
autoimmunity between TSH classifications, a multiple
logistic regression model was used, with AMH and thy-
roid autoimmunity predicting TSH classification. This
model passed the Hosmer-Lemeshow goodness-of-fit
test.
Analyses were conducted using SPSS 22.0 under the
supervision of the center’s senior medical statistician (SD).
A P-value <0.05 was considered statistically significant.
Institutional review board
The presented data only involved retrospective review of
medical records and data retrieval from an anonymized
research database. Patients at CHR sign an informed
consent at initial consultation, which allows for such re-
views if the patient’s medical record remains confidential
and her identity protected. These conditions were met
in this case, allowing for expedited review and approval
by the Institutional Review Board (IRB) of The Center
for Human Reproduction, New York, NY.
Results
Patient characteristics are presented in Table 1. Mean
age for study participants was 38.4 ± 5.0 years. Mean
AMH levels were 1.3 ± 2.0 ng/mL, mean TSH levels
were 1.8 ± 0.9 μIU/mL. Body mass index (BMI) and eth-
nicity were comparable between TSH groups (p = 0.58
and p = 0.49). Thyroid autoimmunity was present in
11.1 % of all patients. TPO antibodies were positive in
11.1 % of patients and TG antibodies in 1.8 % of women.
There were no patients with thyroid receptor antibodies.
Patients with low-normal and high-normal TSH levels
were of comparable age (i.e. 38.3 ± 5.1 vs. 38.9 ± 4.4 years,
P = 0.67). Women with high-normal TSH levels pre-
sented with thyroid autoimmunity in 26.9 %, while thy-
roid autoimmunity was present in only 9.0 % of women
with low-normal TSH levels (P = 0.01). Thyroid auto-
immunity was mainly attributed to TPO antibodies
(Table 1).
Women with TSH <3.0 μIU/mL presented with signifi-
cantly higher mean AMH levels (1.4 ± 2.0 ng/mL) than
those with TSH ≥3.0 μIU/mL (0.8 ± 1.8 ng/mL; P = 0.02).
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Those findings remained significant when the analysis
was adjusted for presence or absence of autoimmunity
and age (P = 0.02) (Table 2).
Not surprisingly, thyroid autoimmunity was found to
be a significant predictor of TSH classification. The esti-
mated odds of a patient with positive thyroid auto-
immunity exhibiting a high-normal TSH was 3.14 times
that of a patient with negative thyroid autoimmunity
and the same AMH level. Conversely, for a single unit
log increase in AMH, odds of having a high-normal
TSH level decreased by 33 % after controlling for thy-
roid autoimmunity.
Discussion
Whether and, if so how, thyroid function affects FOR
has remained unresolved. We in this study attempted to
pierce out how thyroid function, thyroid autoimmunity
and, possibly age, may interphase in answering this
question. In this context it is important to note that this
study was performed in women within euthyroid range
to exclude secondary effects of cofounders that may be
associated with abnormal thyroid function, like for
example hyperprolactinemia.
Consequently, we here, even within normal thyroid func-
tion levels, are able to report a significant association of
TSH levels with FOR, as assessed by AMH. What is gener-
ally considered sub-clinical hypothyroidism, reflected in
TSH levels of ≥3.0μIU/mL, therefore, already appears to
exert negative effects on FOR, resulting in significantly
lower AMH levels. That this effect is thyroid function-
dependent and not a consequence of thyroid autoimmun-
ity was demonstrated in the study by the complete absence
of any effects of adjustment for thyroid autoimmunity on
the significance of the findings. Significance was also not
affected by age, thus suggesting that here observed
association of thyroid function with FOR holds at all
ages. However, women included in our study had a
mean age of 38.4 ± 5 years. It would therefore be in-
teresting to see whether the lack of association can
be confirmed in a study group of young women.
Here reported data are supported by a very recent
publication by Kuroda et al., who also reported a clear
statistical association between elevated TSH levels and
decreases in AMH concentrations [17]. This Japanese
study, however, investigated this association in infertile
as well as fertile women, and unrestricted to the normal
TSH range. Combined, both studies, thus, suggest that
hypothyroidism already from very mild stages on in all
women negatively affects FOR.
These findings explain why thyroid hormone supple-
mentation has been reported to improve pregnancy po-
tential in euthyroid women with high-normal TSH levels
[12]. They, however, also contribute to the ongoing con-
troversy in the medical literature whether thyroid func-
tion or thyroid autoimmunity are more important in
affecting female reproduction [18]. Here presented data
suggest that thyroid function appears to have the upper
hand - at least when it comes to effects on FOR. One
may, however, argue that thyroid autoimmunity has an
impact on thyroid function, as tissue damage results in
TSH level increases in women with thyroid autoanti-
bodies [19]. Karmisholt et al. demonstrated highly sig-
nificant associations between TPO-autoantibodies and
TSH increase. They also reported that a considerable
number of TPO positive women showed declining thy-
roid function over one year while none of the study sub-
jects presented with improved TSH levels [20].
FOR is defined as the cohort of small growing follicles,
consistently recruited from a woman’s primordial follicle
pool. Though the follicular recruitment process in the
human experience is not fully understood yet, the num-
ber of follicles recruited within a given time unit are
believed to directly relate to the size of a woman’s prim-
ordial follicle pool [21]. As the granulosa cells of small
growing follicles produce AMH, this hormone, except at
Table 1 Patient characteristics of 225 women who underwent work up for in vitro fertilization
All (n = 225) TSH < 3μIU/mL (n = 199) TSH≥ 3μIU/mL (n = 26) P-value
Female age (years) 38.4 ± 5.0 38.3 ± 5.1 38.9 ± 4.4 0.67
TSH (μIU/mL) 1.8 ± 0.9 1.6 ± 0.6 3.5 ± 0.5
Thyroid autoimmunity (%) 11.1 % 9.0 % 26.9 % 0.01
Thyroid peroxidase antibodies (%) 11.1 % 9.0 % 26.9 % 0.02
Thyroglobulin antibodies (%) 1.8 % 1.0 % 0.8 % 0.10
AMH (ng/mL) 1.3 ± 2.0 1.4 ± 2.0 0.8 ± 1.8 0.02
Positive Thyroid autoimmunity 0.9 ± 1.3 1.1 ± 1.5 0.5 ± 0.6 0.45
Negative Thyroid autoimmunity 1.4 ± 2.1 1.4 ± 2.1 0.9 ± 2.1 0.04
Values are presented as means ± standard deviation
Table 2 Logistic regression model for the probability of TSH ≥ 3
μIU/mL in 225 euthyroid infertile women
Estimate OR p-value
Thyroid autoimmunity 1.23 3.41 0.02
log (AMH) −0.40 0.67 0.03
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extreme ages, is increasingly considered the most accur-
ate marker of the growing follicle pool and, therefore, of
ovarian function [14]. In general, higher AMH concen-
trations are associated with larger oocyte yields and
improved pregnancy potential [22].
Our here reported results are indirectly also supported
by previous reports on negative impact of hypothyroidism
on prolactin, gonadotropin releasing hormone and sex
steroid levels [23]. Moreover, the human ovary contains
specific binding sites for thyroxin, which suggests direct
effects of thyroid hormone [24].
Here reported data raise the intriguing possibility that
thyroxin supplementation prior to fertility treatments in
women with even only high-normal TSH levels (i.e.,
sub-clinical hypothyroidism) and certainly in women
with overt hypothyroidism, may enhance follicular re-
cruitment and/or growth at small growing follicle stages.
This, as an automatic consequence, would lead to larger
oocyte and embryos yields with in vitro fertilization
(IVF) and, therefore, as one would assume, also to
higher cumulative pregnancy rates.
A report by Revelli et al. a number of years ago, how-
ever, confirmed these assumptions only partially by
demonstrating larger oocyte yields after levothyroxin
supplementation in euthyroid fertility patients with thy-
roid autoimmunity; but pregnancy rates improved only
when thyroxin supplementation was combined with
acetylsalicylic acid and prednisolone treatments [25].
If confirmed, Revelli’s data in combination with here
reported outcomes would suggest that hypothyroidism
negatively affects female fertility by reducing FOR, which
may be correctable by thyroxin supplementation. Fre-
quently associated autoimmunity and/or abnormalities
in inflammatory pathways, however, negatively affect im-
plantation potential or even increase miscarriage risks,
both in the literature strongly associated with thyroid
disease [21]. Unfortunately, the number of patients who
demonstrated thyroid autoimmunity in this study was
too small to assess effects of autoimmunity outright on
clinical pregnancy and live birth rates. A meta-analysis
by Toulis et al., however, supports these conclusions by
confirming higher miscarriage rates in euthyroid IVF
patients with thyroid autoimmunity [26].
Not everybody agrees, however, with the conclusion
that hypothyroidism is associated with poor FOR.
Based on a very recent cross-sectional study in
Belgium, Polyzos et al. reported that neither func-
tional hypothyroid nor thyroid autoimmunity in their
patient population were statistically associated with
FOR [27].
Their findings are, however, not only difficult to inte-
grate with here reported findings but also with above
cited reports in the literature. Moreover, they, them-
selves, note that their study design did not preclude
significant patient selection biases. In addition, their
study failed to statistically adjust outcomes for co-
founders. A 2012 meta-analysis, in contrast, supports
the contention that supplementation with L-thyroxin
improves clinical pregnancy outcomes in association
with IVF in women with subclinical hypothyroidism
and/or thyroid autoimmunity [28].
Magri et al. in the same year concluded that IVF out-
comes were negatively influenced by autoimmune thy-
roid disease but that keeping TSH <2.5mIU/mL may
negate such effects [29]. A Turkish group actually re-
ported increased AMH levels in association with Hashi-
moto’s thyroiditis, and, therefore, suggested that this
autoimmune thyroiditis and polycystic ovary syndrome
(PCOS) may share a common etiology [30]. As previ-
ously noted, Japanese colleagues also very recently re-
ported an association between elevated TSH and low
AMH levels [17], Saglam et al., in contrast, after age-
adjustment reported a strong statistical association (P =
0.008) between autoimmune thyroid disease and AMH
levels [31]. Finally, Magri et al. in a very recent follow up
study to above cited 2012 study, not surprisingly re-
ported that the likelihood of poor response to ovarian
hyperstimulation with gonadotropins (i.e., of poor FOR)
was high in women with low AMH but, apparently, not
related to autoimmune thyroid disease; when FOR was
considered “good,” autoimmune thyroid disease was,
however, associated with decreased response to ovarian
stimulation [32]. This, of course, is also an anticipated
finding because once FOR falls below a minimal thresh-
old, further effects of thyroid autoimmunity can no
longer be expected to be visible.
A principal reason why the here presented study was
limited to patients in euthyroid range was, indeed, to
avoid cofounders that, unrecognized, may affect study
results. Our hypothesis was that in this normal range
the respective influences of thyroid function and auto-
immunity might be the easiest to dissect since secondary
effects on ovarian function, like at very low levels of
FOR in Magri’s study [32], would be less likely.
The clarity and statistical power of here reported re-
sults, their consistency after adjustments for auto-
immunity and age appear to support our hypothesis.
Further research on the subject, however, appears ur-
gently needed, considering the very obvious difficulties
in differentiating effect of thyroid function and auto-
immunity on FOR independently.
Such research, however, as this and above cited studies
suggest, has to consider the likelihood that thyroid func-
tion and thyroid autoimmunity affect female fertility via
different effects and/or pathways. Studies, therefore,
have to be designed accordingly, by statistically control-
ling for distinctively contributing factors, such as FOR,
thyroid autoimmunity and age; but also with attention
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paid to how ovaries are being stimulated, and what other
potential cofounders may be present. Considering the
multiple cofounders that may play a role, only a multi-
center study, involving much larger patient cohorts than
are usually available to single IVF centers will, therefore,
be able to resolve matters.
Conclusion
The present study offers solid statistical evidence that
thyroid function, at least in euthyroid range, plays a
more important role in affecting FOR than thyroid auto-
immunity. This finding further suggests that, even
within what generally is considered normal euthyroid
TSH range, close attention should be paid in infertile
women to TSH values.
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